Telmisartan + Amlodipine Besylate
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Alembic Pharmaceuticals Limited | generic | 20 | SUPPLYING |
| Mylan Pharmaceuticals Inc. | generic | 4 | SUPPLYING |
| Lupin Pharmaceuticals,Inc. | generic | 0 | SUPPLYING |
Shortages, recalls, and registration changes attached to this drug concept.
Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications — Recalling firm: Viatris, Inc. — Nationwide in the USA.
Failed Impurities/Degradation Specifications; 18 month long term stability study. — Recalling firm: Lupin Pharmaceuticals Inc. — Product was distributed to 6 wholesalers/ drug chains and 2 mail order pharmacies that may have further distribute the …
